Abacavir sulfate/lamivudine/zidovudine fixed combination in the treatment of HIV infection

Philip Keiser, Naiel Nassar

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Treatment of HIV infection has typically been carried out using two nucleoside analogs and a protease inhibitor. Such regimens can be complex and have high pill burdens. Use of alternative regimens, such as triple nucleoside-based regimens, can improve adherence and decrease toxicities associated with protease inhibitor therapy. A formulation of abacavir sulfate/lamivudine/zidovudine allows a dosing schedule of one pill twice daily. The components have performed favorably compared with protease inhibitor-based regimens, such as indinavir. Compared with efavirenz-based regimens, abacavir sulfate/lamivudine/zidovudine has not performed as well. The combination is being studied as a cornerstone for induction maintenance strategies, in which switching a patient to abacavir sulfate/lamivudine/zidovudine has been associated with similar virologic outcomes as continuing with either protease inhibitor- or efavirenz-based regimens. Administration of abacavir sulfate/lamivudine/ zidovudine also avoids side effects of antiretroviral therapy, such as hyperlipidemia, but its use is associated with a hypersensitivity reaction in a small number of patients. The combination of abacavir sulfate/lamivudine/zidovudine is an important part of the HIV armamentarium. Its potency and ease of administration make it worth consideration in the treatment of HIV, either by itself or in combination with other agents.

Original languageEnglish (US)
Pages (from-to)477-483
Number of pages7
JournalExpert Opinion on Pharmacotherapy
Volume8
Issue number4
DOIs
StatePublished - Mar 2007
Externally publishedYes

Fingerprint

Zidovudine
efavirenz
HIV Infections
Protease Inhibitors
Nucleosides
HIV
Indinavir
Therapeutics
Hyperlipidemias
Appointments and Schedules
Hypersensitivity
Maintenance
abacavir
lamivudine drug combination abacavir

Keywords

  • Abacavir sulfate
  • HIV
  • Lamivudine
  • Trizivir®
  • Zidovudine

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Abacavir sulfate/lamivudine/zidovudine fixed combination in the treatment of HIV infection. / Keiser, Philip; Nassar, Naiel.

In: Expert Opinion on Pharmacotherapy, Vol. 8, No. 4, 03.2007, p. 477-483.

Research output: Contribution to journalArticle

@article{124882a6ae4146f8ba94dc6482c89cf8,
title = "Abacavir sulfate/lamivudine/zidovudine fixed combination in the treatment of HIV infection",
abstract = "Treatment of HIV infection has typically been carried out using two nucleoside analogs and a protease inhibitor. Such regimens can be complex and have high pill burdens. Use of alternative regimens, such as triple nucleoside-based regimens, can improve adherence and decrease toxicities associated with protease inhibitor therapy. A formulation of abacavir sulfate/lamivudine/zidovudine allows a dosing schedule of one pill twice daily. The components have performed favorably compared with protease inhibitor-based regimens, such as indinavir. Compared with efavirenz-based regimens, abacavir sulfate/lamivudine/zidovudine has not performed as well. The combination is being studied as a cornerstone for induction maintenance strategies, in which switching a patient to abacavir sulfate/lamivudine/zidovudine has been associated with similar virologic outcomes as continuing with either protease inhibitor- or efavirenz-based regimens. Administration of abacavir sulfate/lamivudine/ zidovudine also avoids side effects of antiretroviral therapy, such as hyperlipidemia, but its use is associated with a hypersensitivity reaction in a small number of patients. The combination of abacavir sulfate/lamivudine/zidovudine is an important part of the HIV armamentarium. Its potency and ease of administration make it worth consideration in the treatment of HIV, either by itself or in combination with other agents.",
keywords = "Abacavir sulfate, HIV, Lamivudine, Trizivir{\circledR}, Zidovudine",
author = "Philip Keiser and Naiel Nassar",
year = "2007",
month = "3",
doi = "10.1517/14656566.8.4.477",
language = "English (US)",
volume = "8",
pages = "477--483",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Abacavir sulfate/lamivudine/zidovudine fixed combination in the treatment of HIV infection

AU - Keiser, Philip

AU - Nassar, Naiel

PY - 2007/3

Y1 - 2007/3

N2 - Treatment of HIV infection has typically been carried out using two nucleoside analogs and a protease inhibitor. Such regimens can be complex and have high pill burdens. Use of alternative regimens, such as triple nucleoside-based regimens, can improve adherence and decrease toxicities associated with protease inhibitor therapy. A formulation of abacavir sulfate/lamivudine/zidovudine allows a dosing schedule of one pill twice daily. The components have performed favorably compared with protease inhibitor-based regimens, such as indinavir. Compared with efavirenz-based regimens, abacavir sulfate/lamivudine/zidovudine has not performed as well. The combination is being studied as a cornerstone for induction maintenance strategies, in which switching a patient to abacavir sulfate/lamivudine/zidovudine has been associated with similar virologic outcomes as continuing with either protease inhibitor- or efavirenz-based regimens. Administration of abacavir sulfate/lamivudine/ zidovudine also avoids side effects of antiretroviral therapy, such as hyperlipidemia, but its use is associated with a hypersensitivity reaction in a small number of patients. The combination of abacavir sulfate/lamivudine/zidovudine is an important part of the HIV armamentarium. Its potency and ease of administration make it worth consideration in the treatment of HIV, either by itself or in combination with other agents.

AB - Treatment of HIV infection has typically been carried out using two nucleoside analogs and a protease inhibitor. Such regimens can be complex and have high pill burdens. Use of alternative regimens, such as triple nucleoside-based regimens, can improve adherence and decrease toxicities associated with protease inhibitor therapy. A formulation of abacavir sulfate/lamivudine/zidovudine allows a dosing schedule of one pill twice daily. The components have performed favorably compared with protease inhibitor-based regimens, such as indinavir. Compared with efavirenz-based regimens, abacavir sulfate/lamivudine/zidovudine has not performed as well. The combination is being studied as a cornerstone for induction maintenance strategies, in which switching a patient to abacavir sulfate/lamivudine/zidovudine has been associated with similar virologic outcomes as continuing with either protease inhibitor- or efavirenz-based regimens. Administration of abacavir sulfate/lamivudine/ zidovudine also avoids side effects of antiretroviral therapy, such as hyperlipidemia, but its use is associated with a hypersensitivity reaction in a small number of patients. The combination of abacavir sulfate/lamivudine/zidovudine is an important part of the HIV armamentarium. Its potency and ease of administration make it worth consideration in the treatment of HIV, either by itself or in combination with other agents.

KW - Abacavir sulfate

KW - HIV

KW - Lamivudine

KW - Trizivir®

KW - Zidovudine

UR - http://www.scopus.com/inward/record.url?scp=33947281151&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947281151&partnerID=8YFLogxK

U2 - 10.1517/14656566.8.4.477

DO - 10.1517/14656566.8.4.477

M3 - Article

VL - 8

SP - 477

EP - 483

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 4

ER -